Live Breaking News & Updates on Alvesco Inhalation Aerosol

Stay updated with breaking news from Alvesco inhalation aerosol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Covis Pharma Group Announcements | Covis Pharma Group: COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide)

Covis Pharma Group
COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide)
COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide)
ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced today top-line results from a 400 patient phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ciclesonide metered-dose inhaler in non-hospitalized patients 12 years of age and older with symptomatic COVID-19 infection. ....

United States , Michael Blaiss , Covis Pharma Group The Company , Top Line Safety , Efficacy Data , Using Inhaled Corticosteroid , Pharma Group , Medical College , Augusta University , Inhalation Aerosol , Alvesco Inhalation Aerosol , Dosage Forms , Safety Information , Important Safety Information , Full Prescribing Information , ஒன்றுபட்டது மாநிலங்களில் , பார்மா குழு , மருத்துவ கல்லூரி , அகஸ்டா பல்கலைக்கழகம் , அளவு வடிவங்கள் , பாதுகாப்பு தகவல் , முக்கியமான பாதுகாப்பு தகவல் , முழு ப்ரிஸ்க்ரைபிஂக் தகவல் ,

Covis Pharma Group: COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide)

(0)
ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) Covis Pharma Group (the Company ), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced today top-line results from a 400 patient phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ciclesonide metered-dose inhaler in non-hospitalized patients 12 years of age and older with symptomatic COVID-19 infection.
The primary endpoint of the study was time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, feeling feverish, repeated shaking with chills, muscle pain, headache, sore throat, and new loss of taste or smell, defined as symptom-free for a continuous period of = 24 hours by Day 30. A sub-group analysis showed that time to alleviation of cough was the most improved symptom in the ciclesonide arm compared to the placebo arm by 6 days in 75% ....

United States , Michael Blaiss , Kostenloser Wertpapierhandel , Covis Pharma Group The Company , Pharma Group , Medical College , Augusta University , Inhalation Aerosol , Alvesco Inhalation Aerosol , Dosage Forms , Safety Information , Important Safety Information , Full Prescribing Informationfor , ஒன்றுபட்டது மாநிலங்களில் , பார்மா குழு , மருத்துவ கல்லூரி , அகஸ்டா பல்கலைக்கழகம் , அளவு வடிவங்கள் , பாதுகாப்பு தகவல் , முக்கியமான பாதுகாப்பு தகவல் ,